The Jackson Laboratory, a Maine-based nonprofit biomedical research institution with a major hub in Farmington, recently announced it has completed its acquisition of the New York Stem Cell Foundation (NYSCF), a nonprofit dedicated to advancing cures through stem cell research.
The Jackson Laboratory, a Maine-based nonprofit biomedical research institution with a major hub in Farmington, recently announced it has completed its acquisition of the New York Stem Cell Foundation (NYSCF), a nonprofit dedicated to advancing cures through stem cell research.
In a news release, JAX said the combination, which was first announced in July 2024, creates “one of the most powerful nonprofit engines for biomedical discovery,” combining the lab’s expertise in genetics and mouse models with NYSCF’s advanced stem cell and automation technologies.
Combining the two organizations “marks a turning point for biomedical research,” said Lon Cardon, president and CEO of The Jackson Laboratory. “By combining three powerful approaches — genomics, stem cell innovation, and data-driven AI — we are creating a platform that accelerates discovery from the very start of research and giving scientists stronger tools to turn early insights into breakthroughs for patients.”
Founded in 2005, NYSCF has pioneered the development of scalable stem cell platforms that allow scientists worldwide to study disease, discover drugs and explore regenerative medicine. The foundation has 77 employees.
By joining with JAX, recognized for its deep expertise in genetics, quality standards, and leadership in NIH-funded research, the unified organization will provide the biomedical community with more powerful tools to model human health, test interventions and improve reproducibility.
Established in Bar Harbor, Maine, in 1929, JAX is a global organization with nearly 3,000 employees worldwide and campuses and facilities in Maine, Connecticut, New York, California, Florida and Japan.
